Estrogen receptor degrader increases progression-free survival in advanced breast can
 

Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen

More...

Re: Estrogen receptor degrader increases progression-free survival in advanced breast
 

New option?

Does this mean since I take arimidix that this is a new option for me???
Thanks,

Re: Estrogen receptor degrader increases progression-free survival in advanced breast
 

This is Faslodex and has been around forever. I think it is only for stage 4 disease.